What one share of Galectin Therapeutics holds
We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions.
Galectin Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.43 |
|---|---|
| Cash and investments | $0.20 |
| Book value | −$2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$0.93 | — | — | — | −$0.16 |
| 2011 | — | −$1.06 | $0.00 | −$0.47 | — | −$0.16 |
| 2012 | — | −$0.72 | $0.00 | −$0.50 | — | $0.03 |
| 2013 | — | −$1.30 | $0.00 | −$0.44 | — | $0.05 |
| 2014 | — | −$0.78 | $0.00 | −$0.57 | — | $0.93 |
| 2015 | — | −$0.88 | $0.00 | −$0.70 | — | $0.61 |
| 2016 | — | −$0.77 | — | — | — | $0.31 |
| 2017 | — | −$0.49 | — | — | — | −$0.01 |
| 2018 | — | −$0.38 | — | — | — | $0.13 |
| 2019 | — | −$0.39 | — | — | — | $0.77 |
| 2020 | — | −$0.41 | — | — | — | $0.38 |
| 2021 | — | −$0.52 | — | — | — | $0.01 |
| 2022 | — | −$0.65 | — | — | — | −$0.57 |
| 2023 | — | −$0.74 | — | — | — | −$1.00 |
| 2024 | — | −$0.76 | — | — | — | −$1.66 |
| 2025 | — | −$0.48 | — | — | — | −$1.96 |
Common questions about Galectin Therapeutics
How much does one share of Galectin Therapeutics earn?
Over the last 12 months, Galectin Therapeutics lost $0.43 for each share.
Does Galectin Therapeutics pay a dividend?
Galectin Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Galectin Therapeutics’s book value per share?
Galectin Therapeutics’s book value is negative (−$2.09 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Galectin Therapeutics have?
Each share of Galectin Therapeutics has $0.20 of cash and investments, as of June 30, 2026.
Has Galectin Therapeutics bought back shares?
Galectin Therapeutics’s share count rose about 582% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.